Charlie Munger | Multibagger Shares

May 7, 2026

Chart: Opportunity Cost as Hurdle Rate by fiscal year FY20–FY25, with bars showing values 28, 26, 22, 18, 14 and a green FY25 bar at 11%.

Opportunity Cost as Hurdle Rate: Charlie Munger’s ‘Best Available Alternative’ Test

Charlie Munger's lifetime discipline: every rupee must beat the next-best alternative use, on a risk-adjusted basis. How Indian long-term investors apply the hurdle-rate test using the 10-year G-sec, and why Titan Biotech FY25's audited RoCE spread illustrates the discipline.

April 23, 2026

Horizontal bar chart of yearly multibagger shares (FY20–FY25): FY20 28, FY21 26, FY22 22, FY23 18, FY24 14, FY25 11 (FY25 bar in green).

Invert, Always Invert: Charlie Munger’s Cornerstone Mental Model for Avoiding Small-Cap Disasters in Indian Value Investing

Charlie Munger's favourite mental model — invert the question. Instead of 'how do I find the next multibagger?', ask 'how do I guarantee small-cap losses?' A disciplined Indian inversion checklist, illustrated by Titan Biotech's FY25 audited numbers.

April 6, 2026

Dark blue hero with title 'Our Favourite Holding Period Is Forever' and a horizontal bar chart showing FY20–FY25 values from 28 down to 11, with FY25 in green.

Our Favourite Holding Period Is Forever: Why the Greatest Investors Never Sell Their Best Stocks

📅 Published April 06, 2026 (Monday) Today’s market snapshot — SENSEX: 73,548 (+0.31%) | NIFTY 50: 22,801 (+0.39%) | Titan Biotech (BSE: 524717): ₹529, Market Cap […]

April 6, 2026

Hero title about diversification with a dark navy background and a 2x2 colored grid labeling: Trader (gray), Compounder (green), Drift (light gray), Speculator (orange).

Why Warren Buffett Hates Diversification — And Why You Should Too: The Case for Concentrated Conviction Investing

📅 Published April 06, 2026 (Monday) Today’s market snapshot — SENSEX: 73,073 | NIFTY 50: 22,718 | Titan Biotech (BSE: 524717): ₹529, Market Cap ₹2,187 Cr, […]